▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1881 by analyst upside · 2026-11-08
PBLS
Parabilis Medicines, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+45.1%
implied upside to consensus target
Current Price $28.53
Consensus Target $41.4
Bull Target $45.0
Bear Target $40.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
5
Hold
0
Sell
0
52-Week Low $22.66
52-Week High $42.49
YTD Return -9.7%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-9.51
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $22.66
52-Week High $42.49
Current Price $28.53
Bear Target $40.0
Bull Target $45.0
● Now $28.53 ● Target $41.4
TRADING DATA
Avg Volume 921K
YTD Return -9.7%
Analyst Count 5
Consensus Buy
Upside to Target +45.1%
Last Updated 2026-11-08

ANALYST SUMMARY

Parabilis Medicines, Inc. (PBLS) is currently trading at $28.53 with a Wall Street consensus price target of $41.4, implying potential upside of 45.1% over the next 12 months. 5 analysts currently cover PBLS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $45.0, while the most cautious has a target of $40.0.

PBLS operates in the Healthcare sector with a market capitalisation of $4B. The stock is down 9.7% year-to-date and is currently trading near the lower end of its 52-week range of $22.66 – $42.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ACAD +44.5%
Acadia Pharmaceuticals Inc.
$4B · P/E 10.0x · Buy
INDV +36.4%
Indivior Pharmaceuticals, Inc.
$4B · P/E 10.2x · Buy
NVST +13.4%
Envista Holdings Corporation
$4B · P/E 6.5x · Buy
STVN +47.1%
Stevanato Group S.p.A.
$4B · P/E 23.0x · Buy
AVAH +13.6%
Aveanna Healthcare Holdings Inc.
$3B · P/E 10.5x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PBLS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ● Initiated
Buy 2026-10-22 31% win rate (48 calls)
Guggenheim ● Initiated
Buy 2026-07-06 62% win rate (8 calls)
Leerink Partners ● Initiated
Outperform 2026-07-06 29% win rate (7 calls)
B of A Securities ● Initiated
Buy 2026-07-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
67
out of 100
Coverage depth
14/30
Consensus clarity
26/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →